Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03639948 | Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer(NeoPACT) | unknown | Phase 2 | 120 | University of Kansas Medical CenterOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT03741101 | Treatment of NF1-related Plexiform Neurofibroma With Trametinib(plexifpc) | unknown | Phase 2 | 15 | Region SkaneOTHER | 1 | Apr 11, 2024 |
| clinicaltrials |
| NCT04909684 | Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLC(DEDICATION-1) | unknown | Phase 3 | 750 | Radboud University Medical CenterOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT05467111 | Cardioprotective Effect of Acute Exercise in Breast Cancer Patients(CardioProtEx) | unknown | N/A | 40 | Technical University of MadridOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT05519293 | Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation | unknown | Phase 1 / Phase 2 | 76 | RedCloud BioINDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT05519605 | Bile Duct Drainage After ERCP Failure: EUS-BD vs PTBD(BESTDRAIN) | unknown | — | 61 | Radboud University Medical CenterOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT05552781 | H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC | unknown | Phase 1 / Phase 2 | 76 | RedCloud BioINDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06025682 | Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO(INO-FIRST) | unknown | — | 158 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06268600 | The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma | unknown | N/A | 320 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT04460950 | Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms | unknown | — | 237 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06084923 | Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease Progression | unknown | — | 73 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 0 | Apr 10, 2024 | clinicaltrials |
| NCT06357338 | Differential Expression and Potential Value of c-MYC in Non-Invasive and Invasive Mammary Carcinoma | unknown | — | 70 | Marwa Mahmoud HassanOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06357598 | Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer(PILOT) | unknown | Phase 4 | 30 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT01906814 | Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation | unknown | Phase 3 | 179 | Sun Yat-sen UniversityOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT03481868 | EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors(EPIK) | unknown | N/A | 160 | University Hospital, Clermont-FerrandOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT04387500 | Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma | unknown | Phase 2 | 41 | West China HospitalOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT05075460 | Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma | unknown | Phase 3 | 107 | Peking Union Medical College HospitalOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06353698 | Fasting Mimicking Diet With Chemotherapy in Patients With Leukemia | unknown | N/A | 40 | National Nutrition and Food Technology InstituteOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06355700 | Hepatocellular Carcinoma Liver Organoids(HELIO) | unknown | N/A | 10 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT04573192 | A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression(GLIOSTAR) | unknown | Phase 1 / Phase 2 | 142 | Philogen S.p.A.INDUSTRY | 4 | Apr 8, 2024 | clinicaltrials |
| NCT02266745 | A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts | unknown | Phase 2 | 109 | Promontory Therapeutics Inc.INDUSTRY | 2 | Apr 5, 2024 | clinicaltrials |
| NCT05257785 | Lymfit to Improve the Fitness and Quality of Life in Lymphoma Survivors(Lymfit_RCT) | unknown | N/A | 50 | McGill UniversityOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT06348693 | Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness | unknown | — | 400 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT06349252 | Survival Validation and Gene Mutations of N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer | unknown | — | 1,263 | Fudan UniversityOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT02991924 | Risk Factors of Medistinal Metastasis in Endoscopic Staging of Lung Cancer | unknown | — | 600 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 4, 2024 | clinicaltrials |
| NCT05254119 | DIAGNOSIS, TREATMENT AND OUTCOME OF LUNG CANCER PATIENTS(REGISTURK-LUNG) | unknown | — | 6,000 | Mahmut GumusNETWORK | 1 | Apr 4, 2024 | clinicaltrials |
| NCT03548571 | Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy(DEN-STEM) | unknown | Phase 2 / Phase 3 | 60 | Oslo University HospitalOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT04772235 | Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients(TOTEM) | unknown | Phase 1 | 32 | Instituto Oncológico Dr RosellOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT05043701 | Individualized Systems Medicine Functional Profiling for Recurrent Glioblastoma(ISM-GBM) | unknown | Early Phase 1 | 15 | Oslo University HospitalOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06182306 | Prospective Evaluation of AI R&D Tool for Patient Stratification - MoA Evaluation in Triple Negative Breast Cancer (PEAR-MET)(PEAR-MET) | unknown | — | 30 | Ourotech, Inc.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06334835 | Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells. | unknown | — | 20 | IRCCS SYNLAB SDNOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06344715 | Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC. | unknown | Phase 1 | 78 | SL VAXiGENINDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06241235 | Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma | unknown | Phase 1 / Phase 2 | 48 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06341387 | Volatolomic and Proteomic Profile for Early Diagnosis of Lung Cancer | unknown | — | 200 | European Institute of OncologyOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06341530 | Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 33 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06341660 | To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 30 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06342297 | Dermatoscopy Guided Resection for Skin Cancer | unknown | N/A | 400 | Region Örebro CountyOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06342323 | The Optimal Number of Fiducial Marker for Stereotactic Body Radiotherapy(ONFM-SBRT) | unknown | — | 57 | Peking University Third HospitalOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05057130 | Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors | unknown | Phase 2 / Phase 3 | 50 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 71 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT05626985 | Refinement and Validation of a Diagnostic Model (GAMAD) for Early Detection of Hepatocellular Carcinoma | unknown | — | 2,000 | Singlera Genomics Inc.INDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06339242 | A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis | unknown | Phase 2 | 30 | Jiangsu Province Nanjing Brain HospitalOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06339541 | The ACC Preclinical Research Platform for Precision Oncology(ACC Platform) | unknown | — | 250 | Fondazione del Piemonte per l'OncologiaOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06340243 | Risk Adapted Therapy of Hodgkin Lymphoma in Upper Egypt | unknown | — | 50 | Assiut UniversityOTHER | 0 | Apr 1, 2024 | clinicaltrials |
| NCT06231680 | Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) | unknown | Phase 2 | 132 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 29, 2024 | clinicaltrials |
| NCT04830267 | The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC | unknown | Phase 2 | 39 | Chongqing University Cancer HospitalOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06334757 | Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure | unknown | Phase 2 | 46 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06335277 | Total Body Irradiation Treatments for Patients Treated at European Institute of Oncology | unknown | — | 50 | European Institute of OncologyOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06335927 | HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC | unknown | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Mar 28, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 11, 2024source: clinicaltrials